AGIO vs RARE
AGIO: A commercial-stage biopharmaceutical company focused on transforming the treatment landscape for rare genetic hematologic diseases through its innovative pyruvate kinase activator technology. RARE: Ultragenyx is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for serious, rare, and ultra-rare genetic diseases.
Side-by-side fundamentals
| Metric | AGIO | RARE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $36.05 | $27.65 | |
| Market cap as of 2026-07-23 | $2.2B | $2.8B | |
| PEG as of 2026-07-23 | n/a | -1.23 | |
| Net margin as of 2026-07-23 | -639.8% | -91.0% | RARE higher |
| Gross margin as of 2026-07-23 | +90.0% | +83.6% | AGIO higher |
| Operating margin as of 2026-07-23 | -720.0% | -83.8% | RARE higher |
| ROE as of 2026-07-23 | -34.1% | -414.2% | AGIO higher |
| ROA as of 2026-07-23 | -31.7% | -45.7% | AGIO higher |
| Debt / equity as of 2026-07-23 | 0.00 | 90.54 | AGIO lower |
| Revenue growth (YoY) as of 2026-07-23 | +78.3% | +13.3% | AGIO higher |
| Revenue CAGR (3y) SEC XBRL | +56.0% | +22.8% | AGIO higher |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 0.58 | 0.28 | |
| 1-year return as of 2026-07-22 close | -6.4% | +4.6% | RARE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.